Resistance to chemotherapy is a major obstacle for curative treatment of human gastric cancer (GC). However, the underlying molecular mechanisms are largely unknown. Wingless-type MMTV integration site family members (WNTs) are secreted glycoproteins involved in embryogenesis and, on inappropriate expression in the adult, in cancer. Here, we show expression of WNT6 in GC patient specimens, human GC cell lines and in a mouse model of GC. In human GC cells, WNT6 expression was enhanced by caveolin-1 (Cav1), a scaffold protein of plasma membrane caveolae. WNT6 knock-down and overexpression experiments demonstrated that WNT6 increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics epirubicin (Epi) and doxorubicin (Dox). Epi increased the activity of the human WNT6 promoter through Cav1-dependent binding of b-catenin to the proximal WNT6 promoter. Epi increased both WNT6/Wnt6 and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg). In GC patients, WNT6 expression was positively associated with the tumor stage and the nodal status, and inversely correlated with the response to ECF (Epi, cisplatin, 5-fluorouracil) chemotherapy. These results showed that WNT6 and Cav1 are upregulated by chemotherapeutics and enhance the resistance of GC cells to anthracycline drugs. Understanding the molecular mechanisms driving WNT6/Cav1-induced drug resistance will provide benefits in developing new therapies for GC.
INTRODUCTION
Despite a recent decrease, gastric cancer (GC) remains one of the most common types of human malignancy and the second leading cause of cancer death in the world. 1, 2 Surgery combined with chemotherapy is the current treatment of choice. 3 However, the outcome among patients with advanced GC is poor. Identification of biological markers that have a role in determining the sensitivity or resistance of GC cells to chemotherapeutic treatment is necessary to improve prognosis. The combination of epirubicin (Epi), cisplatin and 5-fluorouracil (5-FU) (ECF) comprises one of the current standard chemotherapy regimens for the palliative as well as for the perioperative treatment of GC. 4, 5 However, the underlying mechanisms of chemoresistance in GC remain largely unknown.
Wingless-type MMTV integration site family members (WNTs) constitute a family of cysteine-rich secreted ligands that are essential for a wide array of developmental and physiological processes. 6, 7 WNTs have diverse functions in governing cell fate, proliferation, migration, polarity and death. Deregulation of WNT signaling in the adult, due to mutations in WNT pathway components such as adenomatous polyposis coli (APC) and b-catenin, is a hallmark of many gastrointestinal cancers. 8 --11 WNT activates at least three intracellular signaling pathways including the b-catenin (canonical WNT pathway), planar cell polarity and Ca 2 þ pathways. The canonical WNT signaling cascade inhibits the activity of the enzyme glycogen synthase kinase-3b, augmenting b-catenin translocation to the nucleus and the transcription of target genes. WNT signaling prevents b-catenin degradation and results in cytoplasmic/nuclear accumulation of b-catenin. 12 WNT signaling has been described to promote chemoresistance in multiple myeloma, 13 neuroblastoma 14 and hepatocellular carcinoma cells. 15 WNT6 is an evolutionary conserved morphogenic factor promoting differentiation, survival and epithelial-to-mesenchymal transitions during embryonal organogenesis. 16, 17 WNT6 has been shown to be overexpressed in different human cancer cell lines. 18 Its function in the embryo predisposes this factor, on inappropriate expression in the adult, for a role in tumorigenesis, metastasis and chemoresistance.
Caveolin (Cav) is present in lipid rafts, which are microdomains of plasma membranes enriched in cholesterol and sphingolipids. 19, 20 Cav1 is their essential structural protein. Cav1 is involved in lipid transport, membrane trafficking, gene regulation and signal transduction. 21, 22 Our previous studies demonstrated that Cav1 expression is reduced in primary human GC compared with normal stomach tissue, but increased in metastatic human GC cell lines. 23 Cav1 is also upregulated in numerous human drugresistant tumor cells, such as multidrug-resistant colon adenocarcinoma cells, doxorubicin (Dox)-resistant breast adenocarcinoma cells and multidrug-resistant lung cancer cells. 24 --27 Cav1 is positively correlated with the tumor grade and its progression stage, and in some cases, the expression of Cav1 was shown to be an independent predictor of poor prognosis, as reviewed in Shatz and Liscovitch. 28 Cav1 upregulation has been associated with poor therapeutic response in patients with lung, kidney, meningioma, prostate and nasopharyngeal cancers. 27,29 --32 Here, we investigated the expression and function of WNT6 in GC, and its relationship to Cav1 expression and chemoresistance to anthracycline chemotherapeutics, Epi and Dox. We observed that Cav1 promotes the resistance of human GC cells to apoptosis induced by anthracycline drugs via augmenting WNT6 expression. This phenomenon was associated with b-catenin-dependent chromatin modifications and transcription. Our data reveal a novel role for Cav1 in promoting WNT6 survival signaling, which facilitates cellular chemoresistance. These results support the notion that targeting Cav1 and/or WNT6 may be a valuable alternative for developing new therapeutic strategies to improve the treatment outcome for GC patients.
RESULTS

WNT6 is expressed in GC cell lines and patient specimens
To determine WNT6 expression, we studied a series of seven wellcharacterized human GC cell lines. Western blot (WB) analysis using the monoclonal WNT6 antibody revealed the presence of a band in the range of the predicted molecular weight for WNT6 (46 kDa) ( Figure 1a ). Consistent with this finding, real-time quantitative PCR (RT --qPCR) confirmed expression of WNT6 mRNA in these cell lines. WNT6 expression was low in AGS and SNU1 cells, originated from a primary gastric tumor, but high in cells derived from a distant metastasis such as MKN45, MKN7 and NCI-N87. Subcellular fractionation confirmed WNT6 protein expression in the membrane, the cytoplasm and in the nucleus (Figure 1b) . To assess whether WNT6 is secreted from GC cells, conditioned medium was collected from MKN45 cells, which express high levels of WNT6 and Cav1. WBs detecting acid-precipitated protein from these media confirmed secretion of WNT6 into the medium as compared with mouse esophagus tissue lysate and HEK293 (two positive controls) (Figure 1c ). WNT6 protein was also detectable in tissue lysates from frozen specimens of four randomly selected GC patients, both in normal and tumor tissue (Figure 1d ). Interestingly, WNT6 mRNA expression was downregulated in 19/26 (73%) of human GC specimens as compared with matched normal gastric tissue, but upregulated in 7/26 (27%) samples (Figure 1e ). This differential WNT6 expression was also evident in immunohistochemical analyses of tissue sections from 53 GC patient tumor specimens (Table 1) . WNT6 was expressed in the normal gastric foveolar epithelium in the apical gland region and in intestinal metaplasia (Figure 2) , both in the cytoplasm and in the nuclei. Plasma cells and macrophages in the lamina propria were positive for WNT6 as well. Wnt6 expression was further confirmed in the mouse stomach tissue predominantly at the base of antral glands. As positive controls, the basal layer of the mouse esophagus and intestinal crypts are shown.
Cav1 promotes WNT6 expression in human GC cells We have shown previously that Cav1 augments stress resistance of human GC cell lines. 23 AGS cells, which are naturally devoid of Cav1, were stably transfected with Cav1 (AGS/Cav1) or empty vector (AGS/EV), respectively. Vice versa, stable knockdown of endogenous Cav1 in MKN45 cells was achieved using Cav1-directed (MKN45/RNA interference (RNAi)) or control RNAi (MKN45/Cav1). To explore the underlying molecular mechanisms of Cav1 action, DNA microarrays were hybridized to total RNAs from the AGS/EV and AGS/Cav1 clonal cell lines. 33 AGS/Cav1 cells displayed a 17-fold increase in Cav1 mRNA together with a panel of mRNAs involved in gastric cell protection and survival (Supplementary Table S1 ). Gene set enrichment analysis revealed that a gene cluster for Dox resistance (DOXO_GASTRIC_UP) was significantly enriched in AGS/Cav1 cells (Figure 3a ). Within this gene cluster the heparin-binding growth factor midkine was identified as the gene consistently upregulated in all drugresistant GC cell lines tested for the three drugs Dox, cisplatin and 5-FU. 34 The second member of the midkine family pleiotrophin was also 26-fold upregulated in our array, indicative of a drugresistant phenotype of the AGS/Cav1 cells. Interestingly, WNT6 was upregulated 15-fold in AGS/Cav1 versus AGS/EV cells together with other gastroprotective factors such as annexin (15-fold) and serpin A1, a serine protease inhibitor (45-fold). These data indicated that Cav1 overexpression induces gene signatures associated with chemoresistance. To further explore the relationship between Cav1 and WNT6, we analyzed WNT6 expression in the GC clonal cell lines. As shown for the AGS/EV cells, MKN45/RNAi cells with low Cav1 levels also had low expression of WNT6 mRNA compared with AGS/Cav1 cells and MKN45/Cav1 cells (Figure 3b ). We then measured WNT6 in parental AGS and HEK293 cells that had been transiently transfected with pcDNA3-Cav1 plasmid. Results from qRT --PCRs (Figure 3c) showed that AGS and HEK cells transfected with Cav1 expressed higher levels of WNT6 mRNA than those transfected with EV. Similar results were obtained for WNT6 protein in WBs. These results supported the notion that Cav1 promotes the expression of WNT6 in GC cells, and raised the hypothesis that WNT6 acts as a downstream mediator of Cav1 in the response of GC cells to chemotherapeutic agents.
WNT6 promotes resistance to anthracycline drugs in human GC cells To further examine the functional role of Cav1-mediated WNT6 upregulation, cells were subjected to genotoxic stress. We measured the cytotoxicity evoked by the three components of the ECF regimen, Epi (Dox), cisplatin and 5-FU, by MTT assay. AGS and MKN45 parental cell lines and derived clones with modified Cav1 status were treated with Epi and Dox for up to 48 h (Figure 4) . Determinations of the IC 50 values for the various cell lines tested showed that GC cells with high Cav1 expression levels were more resistant to Epi-and Dox-induced cell death than cells expressing low Cav1 levels (Supplementary Table S2 ). Concentration response curves in MTT assays showed a significant shift in the IC 50 values for the anthracycline drugs, but not for 5-FU or cisplatin (Supplementary Figure S1) . Parental AGS cells, which are naturally devoid of Cav1, were more sensitive to anthracyclines than parental MKN45 or NCI-N87 cells with endogenous Cav1 (Figure 4a ). AGS/Cav1 and MKN45/Cav1 clones were more resistant than AGS/EV and MKN45/RNAi cells ( Figure 4b ). Anthracyclines are topoisomerase inhibitors and intercalate into the DNA to promote apoptotic cell death. WB analysis showed that Epi triggered an enhanced apoptotic response in MKN45/RNAi cells as compared with MKN45/Cav1, as demonstrated by the parallel increase in the cleavage of both caspase-3 and 8 ( Figure 4c ). These results provided evidence that Cav1 is an important determinant Clinical response data were analysed from ECF-treated GC patients (n ¼ 23). To conclusively establish the involvement of WNT6 in Cav1-mediated drug resistance, we investigated whether the inhibition of WNT6 activity could increase the drug sensitivity of cells. Endogenous WNT6 was knocked down by transient transfection of small interfering RNA (siRNA) oligonucleotides in parental MKN45 and HEK293 cells, resulting in a marked decrease in the level of WNT6 mRNA and protein ( Figure 5a ). Cells with WNT6-knockdown were then exposed to Dox and Epi for up to 48 h. Results from MTT assays showed that, relative to cells transfected with control Cy5-RNAi, HEK293 and MKN45 cells with silenced WNT6 expression displayed a significant increase in Dox-and Epi-induced cell death ( Figure 5b ). These data underlined the involvement of WNT6 in the drug response mechanism and proposed WNT6 as an important mediator of the pro-survival function exerted by Cav1 in human GC cells.
To test whether ectopic overexpression of WNT6 desensitizes cells to chemotherapy, we cloned the full-length mouse Wnt6 complementary DNA (Wnt6) from colon tissue of APC Figure 7a ). We also found that WNT6 protein was increased on drug exposure. To elucidate the molecular mechanisms of this upregulation, the proximal WNT6 promoter (À500/ATG) was cloned from genomic DNA of normal human stomach tissue and inserted into pGL3 luciferase reporter plasmid (hWNT6p-pGL3). AGS and MKN45 cells were transiently transfected with hWNT6p-pGL3 and then treated with Epi for 48 h. Retinoic acid served as a positive control. 17 Epi and retinoic acid evoked a dose-dependent increase inWNT6 reporter gene luciferase activity (Figure 7b) .
b-Catenin is a key regulator in the WNT signal transduction cascade. 7 To determine whether the effect of WNT6 on drug resistance was mediated by a b-catenin-dependent pathway, b-catenin luciferase reporter activity was measured after drug treatment. b-catenin activity was measured with the commonly used TOPflash assay, which utilizes multimeric transcription factor 4 (TCF)-binding sites to drive luciferase activity. Treatment of MKN45 cells with Epi evoked a concentration-dependent increase in b-catenin reporter gene activity as shown before for the WNT6 promoter (Figure 7c ). These results showed that WNT6 upregulation occurs at the transcriptional level and is dependent on active b-catenin. To gain further insight into the involvement of Cav1 in the effect of Epi on b-catenin activity, the mouse Wnt6 expression plasmid was co-transfected with the b-catenin reporter into MKN45/RNAi and MKN45/Cav1 clones ( Figure 7d) . Notably, Epi increased b-catenin reporter gene activity to a higher extent in Wnt6-overexpressing MKN45/Cav1 cells as compared with MKN45/RNAi cells. Collectively, these data corroborated that Cav1 and Wnt6 functionally cooperate to promote b-catenin activity.
Anthracyclines promote b-catenin binding to a conserved TCF site in the WNT6 promoter Using transcription element search system, we identified a putative DNA-binding site for TCF in the proximal WNT6/Wnt6 promoters in both the mouse and human DNA loci (Supplementary Table S3 ). To analyze b-catenin/TCF binding to this region, chromatin immunoprecipitation primers were designed flanking this predicted site. The amplicons comprised the distal (À500/ À250) and proximal (À250/ þ 1) promoter regions (Figure 7e) . To investigate the effect of Epi on b-catenin binding to this promoter region, we performed chromatin immunoprecipitation on the human genomic WNT6 locus in parental MKN45 cells. MKN45 cells were treated for 24 h with 0.5 mM Epi and were subjected to chromatin immunoprecipitation with a polyclonal b-catenin antibody followed by genomic qPCR. Specific amplification products were visualized together with the quantification of normalized cycle threshold values. Compared with vehicle-treated cells, Epi led to an increased binding of b-catenin to the distal (À500/À250) WNT6 promoter region. Collectively, these data corroborated WNT6 as a positive regulator of b-catenin transcriptional activity and chemoresistance (Figure 7f ).
Epi induces expression of Cav1 and Wnt6 in a mouse model of GC We next explored whether the functional interaction between Cav1 and Wnt6, observed to have a role in determining the drug response of human GC cells in vitro, may be also involved in the drug response in vivo. To test this, we evaluated the expression of Cav1 and Wnt6 in CEA424-SV40 TAg transgenic mice. CEA424-SV40 TAg is a transgenic C57BL/6 mouse strain harboring the SV40 T-antigen gene under the control of the human À424/À8 bp CEA gene promoter, which leads to the development of a highly proliferative carcinoma in the pyloric part of the stomach. 36, 37 By day 50, the whole pyloric mucosa has been replaced by carcinoma cells, and mice are moribund after 3 month. Eight weeks old CEA424-SV40 TAg mice were treated with Epi (3 mg/kg, intraperitoneally once a week) for 3 weeks, and tissue samples were extracted from the pylori. Immunohistochemical and RT --qPCR Figure 8a ) and a more intense and frequent nuclear staining of Wnt6 in the tumor regions (Figure 8b ). These results suggested that the functional link between Cav1 and Wnt6 in promoting chemoresistance in GC cells may be also existent in the mouse gastric tumor. Immunohistochemical detection of the proliferation marker Ki-67 demonstrated that the area of residual tumor nests but not the intratumoral proliferation rate was significantly reduced in presence of Epi (Regel et al., unpublished observation). These data indicated that, by upregulation of Cav1/Wnt6 expression, Epi may promote chemoresistance instead of anti-tumor efficacy in vivo. Collectively, these in vivo findings support a possible clinical significance of the in vitro data for novel therapeutic strategies against chemoresistant human GC.
Inverse relationship of WNT6 expression and response to ECF treatment in GC patients
To determine whether WNT6 expression in human GC correlates with a patient's histomorphological response to ECF chemotherapy, a retrospective analysis of 23 GC patients who had been treated with preoperative chemotherapy using a combination of Epi, cisplatin and 5-FU (ECF regimen) was performed. The entire paraffin-embedded tumor beds of patient specimens were stained for WNT6 and evaluated histologically ( Figure 9 ). The histopathologic regression was divided into three grades according to Becker: grade 1, complete or subtotal tumor regression; grade 2, partial tumor regression; and grade 3, minimal or no tumor regression. 38 There was no correlation of WNT6 positivity to patient survival, presumably because of limited case numbers. However, 10 out of 11 (91%) non-responding patients (Becker regression grade 3) had WNT6 staining in the tumor area, whereas 8 out of 12 (67%) responding patients (Becker regression grades 1 and 2) were negative for WNT6 in the tumor area (Table 1) . These findings indicated an inverse relationship between WNT6 expression in GC and clinical response to ECF therapy.
To assess whether WNT6 expression correlates with other clinicopathologic characteristics, a tissue microarray with paraffinembedded biopsies from 30 GC patients, who had not yet (Table 1) . Nonetheless, WNT6 was positively correlated with the T (tumor) stage and the N (nodal) status, both major prognostic factors for poor survival in patients with GC. Future studies have to evaluate the potential of WNT6 as a putative novel response or negative predictive marker in prospective studies in larger series of patients with chemorefractory GC.
DISCUSSION
In this study, we describe to our knowledge for the first time, WNT6 expression in human GC patients, human GC cell lines and a mouse model of GC. We demonstrated that Cav1 and WNT6 positively cooperate in promoting chemoresistance of GC cells to DNA-damaging anthracycline drugs, such as Epi and Dox, through activation of the canonical WNT/b-catenin pathway. Information on the function of WNT6 in general and on the underlying molecular mechanisms of drug response in GC is very limited. Our data represent the first description of a role for WNT6 as an example of a tumor-related re-expression of an embryonic gene in the adult, which facilitates the development of resistance in GC cells to chemotherapeutic drugs. Our results further indicate that the pro-survival function of Cav1 was mediated by the increased expression and/or secretion of the WNT6 glycoprotein. These events may ultimately render GC cells resistant to apoptosis, thus favoring tumor cell survival and further progression of their malignant phenotype. We hypothesize, that the high number of membrane-bound Cav1 molecules in drug-resistant cancer cells may facilitate the secretion of active glycosylated WNT6 molecules into the medium. Alternatively, Cav1 itself may support canonical WNT/b-catenin signaling in an autocrine or paracrine mode, where drug-resistant cells secrete WNT6 into the medium to activate neighbor cells to increase their survival potential. On WNT ligand binding, transmembranous frizzled receptors trigger an intracellular signaling cascade leading to the translocation of active b-catenin to the nucleus and activation of the TCF/lymphoid enhancerbinding factor 1 transcription complex to promote target gene expression. 6, 7 It has been shown that canonical WNTs are first secreted to the cell surface through the endoplasmatic reticulum/ Golgi system, then compartmentalized into endosomes and recycled to the cell surface. 39 Cav1 is one of the major drivers of clathrin-independent endocytosis. 40 Reports claim a dual role of 
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Cav1 in (i) activation of WNT signaling, for example, by endocytosis of ligated WNT receptors (frizzled, LRP6) 41, 42 and in (ii) sequestration of b-catenin to membranes via E-cadherin, thereby reducing the availability of nuclear b-catenin for the formation of a persistent, transcriptionally active complex between b-catenin and TCF/lymphoid enhancer-binding factor. 43 For example, siRNA-knockdown of Cav1 causes a reduction of b-catenin stabilization upon WNT signaling, suggesting that caveolae-mediated endocytosis contributes positively to WNT signaling. 41 Our result support this positive role of Cav1 in activation of WNT signaling by promoting expression and/or secretion of WNT6, and this effect was dependent on b-catenin. Thus, further experimentation is required to ascertain the mechanisms, which act downstream of WNT6 to determine the response of GC cells to chemotherapeutic treatment.
In fact, it has been reported that the induction of apoptosis in GC cells by Dox relates to b-catenin. 44 However, as Epi and Dox are agents that directly damage DNA, it is possible that double-strand breaks introduced by these drugs trigger a specific DNA-damage response involving ataxia telangiectasia mutated kinase and p53. 45, 46 The p53 protein is a known regulator of the Cav1 gene 47 and several WNT-related genes. 48, 49 Thus, an anthracycline damage-specific mechanism may activate WNT-dependent survival signaling by co-upregulation of Cav1 and WNT6. These two proteins then positively cooperate in an auto-or paracrine amplification loop to foster b-catenin-dependent activation of their own synthesis and other genes involved in proliferation and cell survival (Figure 7f) .
Our in vivo data corroborated that anthracyclines function as chemoresistance promoters also in the context of murine GC.
Epi per se upregulated Cav1 and Wnt6 expression in the tumor area. This event was manifest independently of a substantial drugmediated anti-tumor efficacy, as measured by tumor area and Ki-67 proliferation index (Regel et al., unpublished observation). This finding implicated that chemotherapy itself may promote chemoresistance by increasing the expression of secreted resistance/survival proteins in addition to classical multidrug resistance transporters. Despite other reports, as reviewed in Goetz et al., 50 we did not detect a substantial effect of Cav1 on expression levels of a series of 11 multidrug resistance proteins (data not shown). Thus, specific resistance mechanisms may work independently of simple drug extrusion, and thus may constitute putative novel selective targets for anticancer therapy.
In support of this concept, the patient data confirm a positive correlation of WNT6 with GC progression and reduced clinical response to ECF therapy ( Table 1 ). The fact that overall WNT6 mRNA and protein was reduced in GC compared with matched normal gastric tissue, indicates that elevated WNT expression in non-responder patients may be either maintained throughout tumorigenesis or re-acquired after initial loss. WNT acts both as a factor of differentiation 7 or tumor aggressiveness, 51,52 depending on the age of the organism or the progression stage of the cancer. Thus, in the embryo or the adult normal tissue, differentiation will prevail, for example, in stem cell niches of the gastrointestinal tract. In primary cancer sites, WNT6 may impede rapid proliferation at early stages of tumorigenesis and its expression can be silenced, for example, by methylation. 53 In contrast, in advanced stage of GC, under stress conditions, for example, during metastasis or chemotherapy, WNT6 as a driver of cell survival may be re-upregulated to protect GC cells against apoptosis.
In sum, the data from our study evinced Cav1 as an important determinant of the resistance of GC cells to anthracycline-induced apoptosis, and suggest that WNT6 is a critical mediator of the prosurvival functions of Cav1. Although a larger series of human GC specimens needs to be evaluated, the results presented here support the notion that the development of new Cav1-and/or WNT6-targeting strategies may enhance the efficacy of current GC therapies and improve the treatment outcome for patients with GC, particularly those presenting with advanced, metastatic or recurrent disease.
MATERIALS AND METHODS
Ethics statement
The patient study was approved by the Ethics Committee of the Technische Universität Mü nchen and the Universität Heidelberg. Animal studies were conducted in agreement with ethical guidelines of the Technische Universität Mü nchen and approved by the appropriate government authorities.
Subjects
Human GC (TU) and non-tumorous (NT) tissues were collected and stored as described previously. 23 Tissue microarrays from paraffin-embedded specimens from GC patients (n ¼ 30) receiving no previous chemotherapy were provided by GK (Klinikum rechts der Isar, Technische Universität Mü nchen). Specimens from GC patients (n ¼ 23) resected on neoadjuvant ECF therapy were provided by RH (Universitätsklinikum Mannheim, Universität Heidelberg). Clinicopathological data were provided by GK and RH, respectively.
Animals
Transgenic CEA424-SV40 T-antigen (CEA424-SV40 TAg) mice were described previously 36 and maintained on a pure C57BL/6 background. Mice (female, 8 weeks old) were randomized (n ¼ 5 per group) and were treated with Epi for 3 weeks (3 mg/kg, intraperitoneally once a week).
Cell culture
Human embryonic kidney HEK-293 cells and human GC cell lines AGS, NCI-N87, KATO-III, SNU-1, SNU-5 (all from LGC Standards GmbH, Wesel, Germany), MKN-7 and MKN-45 (both from Japanese Collection of Research Bioresources (JCRB)-Cell Bank, National Institute of Biomedical Innovation, Osaka, Japan) and stable clones 23 were cultivated as described. For collection of conditioned medium, MKN45 cells were grown to subconfluency in a 10 cm dish. Conditioned medium was replaced with RPMI containing 0% (v/v) fetal calf serum, 48 h before collection of conditioned medium under sterile conditions. Conditioned mediums were stored at À20 1C. For acid precipitation, medium was thawed and mixed 1:2 with 21% (v/v) trichloric acid, and the mixture was incubated on ice for 16 h. The precipitate was collected by centrifugation at 4000 r.p.m. for 30 min at 4 1C. The supernatant was discarded, and the pellet was dried and resuspended in 3 M Tris-HCl, pH 8.8 for WB analysis.
DNA constructs
The full-length mouse Wnt6 complementary DNA (NM_009526) was amplified from colon tissue of APC min/ þ mice by RT --PCR and inserted into the EcoRI site of the pTarget expression plasmid (Promega GmbH, Mannheim, Germany). The proximal human WNT6 promoter (À500/ATG) (NC_000002.11) was amplified from genomic DNA of normal human stomach tissue and inserted into the XhoI/HindIII-digested pGL3 firefly luciferase reporter plasmid (Promega). Cells were transiently transfected with TurboFect (Thermofisher Scientific, Schwerte, Germany) according to the manufacturer's instructions. Firefly luciferase reporter activity was measured 48 h post transfection and normalized 
MTT cell viability assay
Cells were plated and grown in 96-well plate in 0.1 ml Dulbecco's modified Eagle's medium or RPMI containing 5% (v/v) fetal calf serum at 37 1C for 24 h. Thereafter, the medium was changed and 0.1 ml fresh medium containing drug was added and the cells were incubated for additional 48 h. The number of viable cells was determined by using the 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described. 54, 55 Reverse transcription PCR (RT-PCR) and qPCR Total RNAs were extracted from cell lines and tissues using RNeasy Mini kit (Qiagen GmbH, Hilden, Germany). Total RNA was reverse transcribed using Verso cDNA kit (Thermofisher Scientific), and RT --PCR was performed using the SYBR Green Mix (Roche, Nutley, NJ, USA) on LightCycler480 system (Roche). Each reaction was performed in duplicate. Results were normalized to b2-microglobulin mRNA. Primer sequences are listed in Supplementary Table S4. WNT6 knock-down by siRNA
To ablate endogenous WNT6 expression, 2 Â 10 5 cells per well in a six-well plate were transfected with 50 nM WNT6 siRNA or a control Cy 5-labelled siRNA oligonucleotide (Silencer, Ambion/Applied Biosystems, Darmstadt, Germany) using the Interferin siRNA transfection reagent as recommended by the manufacturer (Peqlab, Erlangen, Germany). Cells were incubated with siRNA for 12 h followed by treatment with Epi and Dox for additional 48 h. The siGENOME SMART pool siRNA WNT6 was purchased from Dharmacon/Thermofisher, Schwerte, Germany.
Western blotting WB was performed as previously described. 23, 56 The following antibodies were used: polyclonal sheep anti-human WNT6 (#AF4109, R&D, Wiesbaden, Germany), polyclonal rabbit anti-WNT6 (#ab50030, Abcam, Cambridge, UK), cleaved caspase-3 (Asp175), cleaved caspase-8 (Asp391) (Cell Signaling Technology, Beverly, MA, USA), Hsp90 (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Immunohistochemistry
The method was performed as described previously. 57 Anti-WNT6 (rabbit polyclonal, 1:100; Abcam) was used as primary antibody. Images were collected using a Zeiss Axio Imager A1 microscope, AxioCam MRC camera and Axiovision Rel 4.8 acquisition software (Zeiss, Luton, UK).
Chromatin immunoprecipitation
Cells were treated for 24 h with Epi before cross-linking, lysis and sonication, as described previously. 58 Chromatin fragments were immunoprecipitated with b-catenin antibody (C-18, Santa Cruz Biotechnology).
Statistical analysis
The software (GraphPad Software, Inc., La Jolla, CA, USA) was used to analyze the data. The *P-value o0.05 was considered statistically significant. All values are given as means ±s.e. from at least five animals per group or at least three independent cell experiments. 
